• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

What Is a Biosimilar?

by Jennifer Fink • August 16, 2017

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

The European experience, though, suggests a trend toward decreasing price as the biosimilars market matures. “As the market has evolved, we’ve seen discounts of 30 percent, even 75 percent,” said Dr Fuhr. Furthermore, in some cases, manufacturers of reference biologics are decreasing the cost of their drugs as well. As a result, he said, “access is increasing and costs are going down.”

You Might Also Like

  • What Is a Biosimilar?
  • What Otolaryngologists Need to Know about Biologics and Allergic Rhinitis
  • Are Biologics Viable Options for Treating Pediatric Illness?
  • Are New Biologics a Game Changer for Treating Nasal Polyposis?
Explore This Issue
August 2017

He predicts that cost savings will appear here as well. “In five years, you should see considerable decreases in price.”

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Home Slider Tagged With: biologic drugs, biologics, biosimilar, otolaryngology, pharmaceuticalsIssue: August 2017

You Might Also Like:

  • What Is a Biosimilar?
  • What Otolaryngologists Need to Know about Biologics and Allergic Rhinitis
  • Are Biologics Viable Options for Treating Pediatric Illness?
  • Are New Biologics a Game Changer for Treating Nasal Polyposis?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Would you choose a concierge physician as your PCP?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Shifting the Treatment Goalpost Toward Medical Management of Recurrent Respiratory Papillomatosis

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • A Journey Through Pay Inequity: A Physician’s Firsthand Account

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Excitement Around Gene Therapy for Hearing Restoration
    • “Small” Acts of Kindness
    • How To: Endoscopic Total Maxillectomy Without Facial Skin Incision
    • Science Communities Must Speak Out When Policies Threaten Health and Safety
    • Observation Most Cost-Effective in Addressing AECRS in Absence of Bacterial Infection

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939